Group 1 - Gujia Home achieved a net profit of 1.02 billion yuan in the first half of 2025, a year-on-year increase of 13.89% [1] - Gujia Home's revenue for the first half of 2025 was 9.80 billion yuan, up 10.02% year-on-year [1] - Phoenix Holdings reported a net profit of 11.04 million yuan, successfully turning a profit [1] - Phoenix Holdings' revenue increased by 200.78% year-on-year to 291 million yuan [1] - Zheshang Securities recorded a net profit of 1.15 billion yuan, a year-on-year growth of 46.49% [1] - Zheshang Securities' revenue decreased by 23.66% to 6.11 billion yuan [1] Group 2 - Tianjin Port's net profit was 503 million yuan, a year-on-year decrease of 18.33% [3] - Tianjin Port's revenue for the first half of 2025 was 6.18 billion yuan, an increase of 4.33% year-on-year [3] - Xuantai Pharmaceutical reported a net profit of 45.59 million yuan, down 15.82% year-on-year [5] - Xuantai Pharmaceutical's revenue was 220 million yuan, a slight increase of 0.74% year-on-year [5] Group 3 - Yilida achieved a net profit of 40.03 million yuan, a year-on-year increase of 18.32% [7] - Yilida's revenue for the first half of 2025 was 758 million yuan, up 12.56% year-on-year [7] - Zhongji United reported a net profit of 262 million yuan, a significant year-on-year increase of 86.61% [9] - Zhongji United's revenue was 818 million yuan, a year-on-year growth of 43.52% [9] Group 4 - China Shipbuilding Special Gas reported a net profit of 178 million yuan, a slight decrease of 0.55% year-on-year [10] - China Shipbuilding Special Gas' revenue was 1.04 billion yuan, an increase of 12.60% year-on-year [10] - Xinyuan Intelligent Manufacturing achieved a net profit of 9.79 million yuan, a year-on-year increase of 284.45% [11] - Xinyuan Intelligent Manufacturing's revenue was 329 million yuan, up 388.33% year-on-year [11] Group 5 - Jiudian Pharmaceutical reported a net profit of 291 million yuan, a year-on-year increase of 2.57% [13] - Jiudian Pharmaceutical's revenue was 1.51 billion yuan, a year-on-year growth of 10.67% [13] - Boya Biological reported a net profit of 225 million yuan, down 28.68% year-on-year [15] - Boya Biological's revenue was 1.01 billion yuan, an increase of 12.51% year-on-year [15] Group 6 - True Love Home achieved a net profit of 197 million yuan, a year-on-year increase of 484.48% [17] - True Love Home's revenue was 390 million yuan, up 21.82% year-on-year [17] - Dongfang Electronics reported a net profit of 302 million yuan, a year-on-year increase of 19.65% [19] - Dongfang Electronics' revenue was 3.16 billion yuan, a year-on-year growth of 12.18% [19] Group 7 - Watte Holdings achieved a net profit of 18.41 million yuan, a year-on-year increase of 23.94% [21] - Watte Holdings' revenue was 906 million yuan, up 12.29% year-on-year [21] - Tianqin Equipment reported a net profit of 16.36 million yuan, a year-on-year increase of 2.78% [22] - Tianqin Equipment's revenue was 111 million yuan, a year-on-year growth of 18.42% [22] Group 8 - Yingfeng Environment achieved a net profit of 382 million yuan, a year-on-year increase of 0.43% [24] - Yingfeng Environment's revenue was 6.46 billion yuan, up 3.69% year-on-year [24] - Kexin Machinery reported a net profit of 52.20 million yuan, a year-on-year decrease of 46.18% [26] - Kexin Machinery's revenue was 592 million yuan, down 17.26% year-on-year [26] Group 9 - Tengda Construction reported a net profit of 108 million yuan, a year-on-year decrease of 0.69% [27] - Tengda Construction's revenue was 1.61 billion yuan, down 5.20% year-on-year [27] - Canaan Technology achieved a net profit of 7.35 million yuan, a year-on-year decrease of 38.46% [29] - Canaan Technology's revenue was 560 million yuan, up 1.29% year-on-year [29] Group 10 - Metro Design reported a net profit of 221 million yuan, a year-on-year increase of 6.58% [30] - Metro Design's revenue was 1.32 billion yuan, up 5.31% year-on-year [30] - China Shipbuilding Special Gas plans to use up to 2.9 billion yuan of idle funds for cash management [31] - The company intends to invest in safe, liquid, principal-protected products [31] Group 11 - Jiuchuang Biotechnology received a medical device registration certificate for its lupus anticoagulant detection kit [32] - The product is intended for in vitro qualitative detection of lupus anticoagulant in human plasma [32] - Xinowei's subsidiary received approval for clinical trials of its innovative drug [33] - The drug is a humanized monoclonal antibody intended for treating multiple cancers [33] Group 12 - Dongcheng Pharmaceutical's subsidiary received FDA approval for clinical trials of its targeted radiopharmaceutical [34] - The drug is intended for treating advanced prostate cancer [34] - Shandong Road and Bridge received approval to issue bonds up to 4 billion yuan [35] - The company specializes in road and bridge engineering construction [35] Group 13 - Diou Home plans to invest 500 million yuan to establish a subsidiary focused on generative AI [36] - The investment aims to transform the company into a full-stack industrial intelligent service provider [36] - Dayilong achieved a net profit of 90.87 million yuan, a year-on-year increase of 217.89% [37] - Dayilong's revenue was 957 million yuan, up 57.35% year-on-year [37] Group 14 - Chaohongji reported a net profit of 331 million yuan, a year-on-year increase of 44.34% [38] - Chaohongji's revenue was 4.10 billion yuan, up 19.54% year-on-year [38] - Taiji Group reported a net profit of 139 million yuan, a year-on-year decrease of 71.94% [39] - Taiji Group's revenue was 5.66 billion yuan, down 27.63% year-on-year [39] Group 15 - Suneng Co. reported a net profit of 93.19 million yuan, a year-on-year decrease of 90.13% [41] - Suneng Co.'s revenue was 5.57 billion yuan, down 17.15% year-on-year [41] - Three Gorges Water Conservancy reported a net profit of 47.93 million yuan, a year-on-year decrease of 79.07% [42] - Three Gorges Water Conservancy's revenue was 4.90 billion yuan, down 6.10% year-on-year [42] Group 16 - Furida reported a net profit of 108 million yuan, a year-on-year decrease of 15.16% [44] - Furida's revenue was 1.79 billion yuan, down 7.05% year-on-year [44] - Chenzhou Electric International achieved a net profit of 25.92 million yuan, a year-on-year increase of 29.55% [46] - Chenzhou Electric International's revenue was 1.96 billion yuan, up 1.26% year-on-year [46] Group 17 - Farlantek achieved a net profit of 122 million yuan, a year-on-year increase of 41.05% [47] - Farlantek's revenue was 1.18 billion yuan, up 46.63% year-on-year [47] - Huitai Medical reported a net profit of 425 million yuan, a year-on-year increase of 24.11% [48] - Huitai Medical's revenue was 1.21 billion yuan, up 21.26% year-on-year [48] Group 18 - Dameng Data's director is under investigation for suspected violations [49] - The company's daily operations remain normal [49] - Maiwei Co. reported a net profit of 394 million yuan, a year-on-year decrease of 14.59% [50] - Maiwei Co.'s revenue was 4.21 billion yuan, down 13.48% year-on-year [50] Group 19 - Waiservice Holdings achieved a net profit of 384 million yuan, a year-on-year increase of 5.51% [52] - Waiservice Holdings' revenue was 12.25 billion yuan, up 16.15% year-on-year [52] - Huakang Co. reported a net profit of 134 million yuan, a year-on-year decrease of 3.38% [53] - Huakang Co.'s revenue was 1.87 billion yuan, up 37.32% year-on-year [53] Group 20 - Bluelight Optical achieved a net profit of 103 million yuan, a year-on-year increase of 110.27% [54] - Bluelight Optical's revenue was 577 million yuan, up 52.54% year-on-year [54] - Shunwang Technology reported a net profit of 162 million yuan, a year-on-year increase of 69.22% [55] - Shunwang Technology's revenue was 1.01 billion yuan, up 25.09% year-on-year [55] Group 21 - Anbiping reported a net loss of 12.50 million yuan in the first half of 2025 [56] - Anbiping's revenue was 159 million yuan, down 30.11% year-on-year [56] - Jinhua Co. reported a net profit of 6.20 million yuan, a year-on-year decrease of 34.53% [57] - Jinhua Co.'s revenue was 241 million yuan, down 1.90% year-on-year [57] Group 22 - Xiehe Electronics achieved a net profit of 28.96 million yuan, a year-on-year decrease of 8.31% [59] - Xiehe Electronics' revenue was 451 million yuan, up 12.13% year-on-year [59] - Huguang Co. reported a net profit of 276 million yuan, a year-on-year increase of 8.40% [60] - Huguang Co.'s revenue was 3.63 billion yuan, up 6.20% year-on-year [60]

（文章来源：每日经济新闻） 宣泰医药8月22日晚间发布半年度业绩报告称，2025年上半年营业收入约2.2亿元，同比增加0.74%；归 属于上市公司股东的净利润约4559万元，同比减少15.82%；基本每股收益0.1元，同比减少16.67%。 ...

上海宣泰医药科技股份有限公司 信息披露暂缓与豁免管理制度 第一章 总则 第二章 暂缓、豁免披露信息的范围 1 第一条 为规范上海宣泰医药科技股份有限公司（以下简称"公司"）的信 息披露暂缓与豁免行为，促进公司依法规范运作，维护公司及投资 者的合法权益，依据《中华人民共和国证券法》《上市公司信息披 露管理办法》《上市公司信息披露暂缓与豁免管理规定》《上海证券 交易所科创板股票上市规则》（以下简称"《上市规则》"）和《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作 （2025 年 5 月修订）》等法律、法规、规范性文件及《上海宣泰医 药科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 制定本制度。 第二条 公司和其他信息披露义务人按照《上市规则》及上海证券交易所（以 下简称"上交所"）其他相关业务规则的规定，暂缓、豁免披露临 时报告，在定期报告、临时报告中豁免披露中国证券监督管理委员 会和上交所规定或者要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当审慎确定信息披露暂缓、豁免事项， 履行内部审核程序后实施，并接受上交所对有关信息披露暂缓、豁 免事项的事后监管。 第 ...

Core Insights - The company reported a revenue of 220 million yuan for the first half of 2025, reflecting a year-on-year growth of 0.74% [1] - The net profit attributable to shareholders decreased by 15.82% to 45.5857 million yuan, with basic earnings per share at 0.1 yuan [1] - The company plans to distribute a cash dividend of 0.25 yuan per 10 shares (tax included) to all shareholders [1] Revenue and Profit Analysis - The significant decline in sales revenue for the product Posaconazole enteric-coated tablets was attributed to its failure to win a bid in the 10th batch of centralized procurement scheduled for December 2024, leading to a 73.09% decrease in domestic sales revenue and a 28.54 percentage point drop in gross margin [1] - Sales revenue and profit-sharing income for Mesalazine enteric-coated tablets in the U.S. market fell by 58.36% and 19.90% respectively, due to increased competition from approved generic manufacturers and rising tariffs [1]

格隆汇8月22日丨宣泰医药(688247.SH)公布2025年半年度报告，上半年实现营业收入2.2亿元，同比增长 0.74%；归属于上市公司股东的净利润4558.57万元，同比下降15.82%；归属于上市公司股东的扣除非经 常性损益的净利润3952.3万元，同比下降19.00%；基本每股收益0.10元。公司拟向全体股东每10股派发 现金红利0.25元（含税）。 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-033 上海宣泰医药科技股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会印发的《上市公司募集资金监管规则》和上海 证券交易所发布的《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等相关法律法规的规定及要求，上海宣泰医药科技股份有限公司（以下 简称"公司"）董事会将公司 2025 年半年度募集资金存放与实际使用情况专项说 明如下： 一、募集资金基本情况 二、募集资金存放和管理情况 （一）募集资金的管理情况 为规范募集资金的管理和使用，公司对募集资金实行专户存储。公司根据《公 司法》《证券法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上 市规则》等有关法律、法规和规范性文件的规定，结合公司实际情况，制定了《上 海宣泰医药科技股份有限公司募集资金管理制度》（以下简称"《募集资金管理制 度》"），对募集资金实行专户存储，募集资金的存放、使用、项目 ...

2025 年上半年，核心产品如熊去氧胆酸胶囊、西格列汀二甲双胍缓释片销 量持续攀升，盐酸安非他酮缓释片、盐酸帕罗西汀肠溶缓释片等产品销量同比增 长显著；在市场竞争加剧的背景下，核心产品泊沙康唑肠溶片销量有一定幅度下 降，但凭借稳定的终端需求，销量仍保持在百万级以上；达格列净二甲双胍缓释 片等 2024 年新获批产品迅速实现商业化销售，逐步形成新的增长点；同时，碳 酸司维拉姆片凭借在集采中中标，进一步扩大市场份额。 一、聚焦主业，不断夯实核心竞争力 2025 年上半年，公司继续秉承"研发驱动、全球布局"的核心战略，实现 营业收入 21,960.70 万元，同比增长 0.74%；归属于母公司所有者的净利润为 4,558.57 万元，同比下降 15.82%。 （一）研发创新驱动，技术平台与产能建设稳步推进 上海宣泰医药科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的半年度评估报告 为践行以投资者为本的发展理念，持续优化经营、规范治理和积极回报投资 者，维护全体股东利益，上海宣泰医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 30 日发布了《2025 年度"提质增效重回报"行动方案 ...

公司代码：688247 公司简称：宣泰医药 上海宣泰医药科技股份有限公司 2025 年半年度报告 1 / 189 上海宣泰医药科技股份有限公司2025 年半年度报告 上海宣泰医药科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司主营业务、核心竞争力不存在重大不利变化，持续经营能力不存在重大风险。公司已在 本报告"第三节管理层讨论与分析"-"四、风险因素"中详细披露了生产经营过程中可能面临的 各种风险，提请投资者查阅。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人郭明洁、主管会计工作负责人吴一鸣及会计机构负责人（会计主管人员）卫培 华声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经公司第二届董事会第十八次会议决议，公司 2025 年半年度拟以实施权益分派股权登记日登 记的总股本扣减公司回购专用证券账户中股份为基数分配利润，本次利润分 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-034 上海宣泰医药科技股份有限公司 关于 2025 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 公司拟向全体股东每 10 股派发现金红利 0.25 元（含税）。根据《上海证券 交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，上市公司回购 每股分配比例：每股派发现金红利 0.025 元（含税）。不进行资本公积金 转增股本，不送红股。 因上海宣泰医药科技股份有限公司（以下简称"公司"）实施股份回购 事项，根据相关规定，公司通过回购专用证券账户持有的本公司股份不 参与本次利润分配。本次利润分配以实施权益分派股权登记日的总股本 扣减公司回购专用证券账户中股份为基数，具体日期将在权益分派实施 公告中明确。 如在实施权益分派的股权登记日前公司总股本扣减公司回购专用证券 账户中的股份数量发生变动的，公司拟维持每股分配比例不变，调整拟 分配的利润总额，并将在权益分派实施公告中明确具体调整情况 ...

宣泰医药公告，2025年上半年营业收入2.2亿元，同比增长0.74%。净利润4558.57万元，同比下降 15.82%。公司拟向全体股东每10股派发现金红利0.25元（含税），拟派发现金红利合计1122.51万元 （含税），占2025年1-6月归属于母公司股东的净利润比例为24.62%。 ...